Pralsetinib for the treatment of non-small cell lung cancer
Copyright 2021 Clarivate Analytics..
The identification of oncogenic drivers and the subsequent development of targeted therapies have been established as biomarker-based care for metastatic non-small cell lung cancer (NSCLC) patients. Rearranged during transfection (RET) events have been reported to be oncogenic drivers in NSCLC and were more common in patients who i) were young; ii) had adenocarcinoma histology; and iii) had never smoked. Phase II studies indicated the limited efficacy of multi-targeted tyrosine kinase inhibitors in patients with NSCLC that have a confirmed RET event. Consequently, there has been ongoing research to develop more potent and specific RET tyrosine kinase inhibitors. Recently, a novel and specific RET inhibitor, pralsetinib (BLU-667), has been reported to have excellent efficacy and low off-target toxicity in RET cancer patients. In this review, we summarize the clinical data regarding the use of pralsetinib in NSCLC patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 57(2021), 9 vom: 01. Sept., Seite 559-569 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fu, X-Y [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.10.2021 Date Revised 01.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2021.57.9.3306764 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331276313 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331276313 | ||
| 003 | DE-627 | ||
| 005 | 20231225213116.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2021.57.9.3306764 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331276313 | ||
| 035 | |a (NLM)34586104 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fu, X-Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pralsetinib for the treatment of non-small cell lung cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.10.2021 | ||
| 500 | |a Date Revised 01.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2021 Clarivate Analytics. | ||
| 520 | |a The identification of oncogenic drivers and the subsequent development of targeted therapies have been established as biomarker-based care for metastatic non-small cell lung cancer (NSCLC) patients. Rearranged during transfection (RET) events have been reported to be oncogenic drivers in NSCLC and were more common in patients who i) were young; ii) had adenocarcinoma histology; and iii) had never smoked. Phase II studies indicated the limited efficacy of multi-targeted tyrosine kinase inhibitors in patients with NSCLC that have a confirmed RET event. Consequently, there has been ongoing research to develop more potent and specific RET tyrosine kinase inhibitors. Recently, a novel and specific RET inhibitor, pralsetinib (BLU-667), has been reported to have excellent efficacy and low off-target toxicity in RET cancer patients. In this review, we summarize the clinical data regarding the use of pralsetinib in NSCLC patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antitumor drugs | |
| 650 | 4 | |a Non-small cell lung cancer (NSCLC) | |
| 650 | 4 | |a Pralsetinib | |
| 650 | 4 | |a Rearranged during transfection (RET) inhibitors | |
| 650 | 4 | |a Solid tumors therapy | |
| 650 | 4 | |a Tyrosine kinase inhibitors | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a pralsetinib |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-ret |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Dong, X-D |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, L |e verfasserin |4 aut | |
| 700 | 1 | |a Ashby, C R |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Z-S |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 57(2021), 9 vom: 01. Sept., Seite 559-569 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2021 |g number:9 |g day:01 |g month:09 |g pages:559-569 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2021.57.9.3306764 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2021 |e 9 |b 01 |c 09 |h 559-569 | ||